UBS AM’s DiaMedica Therapeutics DMAC Stock Holding History

UBS AM’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.43K	Hold	203	–	–	﹤0.01%	3584
2026 Q1	$1.37K	Buy	203 +47	+30%	+$372	﹤0.01%	3649
2025 Q4	$1.24K	Buy	+156	New	+$1.17K	﹤0.01%	3165

Other funds holding DMAC

CLG

Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

UBS AM's DMAC Position: Q2 2026 in Review

UBS AM held its DiaMedica Therapeutics (DMAC) position steady in Q2 2026 at 203 shares worth $1.43K. The position accounts for ﹤0.01% of the portfolio, ranked #3584.

UBS AM first reported a position in DMAC in Q4 2025 and has held it in 3 quarters since. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

UBS AM held 203 shares of DiaMedica Therapeutics worth $1.43K as of Q2 2026.
UBS AM left its DiaMedica Therapeutics share count unchanged in Q2 2026.
DiaMedica Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3584 holding.
UBS AM first reported a position in DiaMedica Therapeutics in Q4 2025 and has held it in 3 quarters since.
89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.